Elevance Health Inc. (ELV) Balance Sheet

The balance sheet continues to expand, but the pace is clearly decelerating. Sequential asset growth of just 0.5% in 2026Q2, following a 3.4% jump in 2026Q1, indicates that the company is no longer accumulating assets at the rate seen in prior quarters. This aligns with the revenue slowdown noted in the income statement analysis, where premium growth fell to 1.4% year-over-year. Equity grew modestly to $44.9B, but the liability side expanded faster, suggesting that reserve growth is outpacing capital generation, which may pressure future solvency ratios.

The investment portfolio line item is essentially zero, which is implausible for a health insurer that must hold reserves in liquid assets. This suggests that the data provided may be incomplete or that investments are held in subsidiaries not consolidated in this line. Investors should monitor the actual investment allocation and yield, as the absence of meaningful investment income in the data limits the ability to assess portfolio quality and duration risk. The lack of investment income data further obscures the true earnings power of the balance sheet.

The claims reserve line shows a sharp increase in 2026Q1, but the subsequent quarter's loss ratio of 10.9% is anomalously low, implying that the company released a substantial amount of prior-year reserves. This pattern, also noted in the income statement analysis, raises questions about the sustainability of earnings. If reserve releases are masking underlying claims deterioration, the balance sheet may be less robust than it appears. The volatility in claims paid, from $41.1B in 2026Q1 to $5.5B in 2026Q2, further complicates the assessment of reserve adequacy.

While equity has grown steadily, the pace of growth is slowing, and the equity-to-assets ratio is modest compared to industry leaders. The company's ability to absorb shocks or fund growth through retained capital appears adequate but not robust. The deceleration in premium growth and the reliance on reserve releases for earnings suggest that organic capital generation may weaken. Investors should monitor the RBC ratio, which is not disclosed here, to assess whether the capital buffer remains sufficient for the risk profile.

The absence of cash and investment data makes it impossible to assess the company's ability to meet near-term claims obligations. Health insurers typically hold significant liquid assets to cover claims, but the reported figures suggest either a data gap or a highly unusual asset structure. The volatility in claims paid, with a swing from $41.1B to $5.5B, underscores the need for a robust liquidity buffer. Without explicit disclosure, investors should treat the liquidity position as a key uncertainty.